A trial of G1T38 in combination with Tagrisso for the treatment of certain types of non-small cell lung cancer

Trial Profile

A trial of G1T38 in combination with Tagrisso for the treatment of certain types of non-small cell lung cancer

Planning
Phase of Trial: Phase I/II

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs G1T 38 (Primary) ; Osimertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Nov 2017 New trial record
    • 08 Nov 2017 According to a G1 Therapeutics media release, the company has submitted an Investigational New Drug (IND) application to the US FDA for G1T38 and Tagrisso combination in non-small cell lung cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top